US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Clene Inc. - Common Stock (NQ:CLNN)

3.870 -0.040 (-1.02%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clene Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Plans 2025 NDA Submission Following Positive ALS Trial Data
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Unveils Progress on CNM-Au8(R), Eyes Potential Fast-Track FDA Approval
Via Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Delivers Significant Survival Benefits in New Analyses of Healey ALS Platform Trial Data
Via Investor Brand Network
MS Drug Could Counter Poor Working Memory
Via Investor Brand Network
News headline image
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
Via ACCESS Newswire
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Reports CNM-Au8 Significantly Improves Survival in ALS Patients
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) to Present CNM-Au8(R) Updates at 37th Annual Roth Conference
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Collaborates to Support Potential Accelerated Pathway for ALS Treatment Candidate
Via Investor Brand Network
Bacterial Imbalances Have a Link to Multiple Sclerosis, Study Finds
Via Investor Brand Network
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Participate in 37th Annual Roth Conference
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) to Highlight Latest Achievements, Next Steps for CNM-Au8(R), at Q1 Virtual Investor Summit on March 11
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Leverages APST’s NfL Database to Support FDA-Recommended Analyses for ALS Drug
Via Investor Brand Network
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO and CFO to Present at Investor Summit Virtual on March 11
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO and CFO to Present at Investor Summit Virtual on March 11
Via Investor Brand Network
News headline image
Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11
Via ACCESS Newswire
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Partners with APST Research to Advance ALS Drug Approval Process
Via Investor Brand Network
New Study to Explore the Link Between Sleep Disorder and Parkinson’s
Via Investor Brand Network
News headline image
IBN Coverage: Clene (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS
Via Investor Brand Network
Study Sheds Light on How Mitochondrial Changes Contribute to Muscle Aging
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R)
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Improves Cash Position and Runway with New Debt Facility for CNM-Au8(R) Data Collection to Support Accelerated Approval Application
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Secures $10 Million Debt Facility to Advance Neurodegenerative Disease Treatments
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Receives FDA Guidance on Accelerated Approval Pathway for CNM-Au8(R) for ALS
Via Investor Brand Network
New Technology Programs Immune Cells to Combat Brain Cancer, MS
Via Investor Brand Network
Topics Death
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Advances CNM-Au8 in ALS with FDA Guidance on Accelerated Approval Pathway
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Reports Q3 2024 Results and Progress on ALS Treatment Pathway
Via Investor Brand Network
European Commission Imposes Hefty Fine on Firm for Blocking Rival MS Drug Developer
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker with FDA Leadership
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >